Literature DB >> 20818419

PRIMA-1(MET)/APR-246 targets mutant forms of p53 family members p63 and p73.

N Rökaeus1, J Shen, I Eckhardt, V J N Bykov, K G Wiman, M T Wilhelm.   

Abstract

The low molecular weight compound PRIMA-1 and the structural analog PRIMA-1(MET), also named APR-246, reactivate mutant p53 through covalent binding to the core domain and induce apoptosis in tumor cells. Here, we asked whether PRIMA-1(MET)/APR-246 can rescue mutant forms of the p53 family members p63 and p73 that share high sequence homology with p53. We found that PRIMA-1(MET)/APR-246 can restore the pro-apoptotic function to mutant TAp63γ and TAp73β in tumor cells but has less effect on TAp73α. Moreover, PRIMA-1(MET)/APR-246-stimulated DNA binding of mutant TAp63γ and induced expression of the p53/p63/p73 downstream targets p21 and Noxa. The reactivation of mutant p53, p63 and p73 by PRIMA-1(MET)/APR-246 indicates a common mechanism, presumably involving homologous structural elements in the p53 family proteins. Our findings may open avenues for therapeutic intervention in human developmental disorders with mutations in p63.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20818419     DOI: 10.1038/onc.2010.382

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  27 in total

1.  Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.

Authors:  Richard J Jones; Chad C Bjorklund; Veerabhadran Baladandayuthapani; Deborah J Kuhn; Robert Z Orlowski
Journal:  Mol Cancer Ther       Date:  2012-08-28       Impact factor: 6.261

Review 2.  A balancing act: orchestrating amino-truncated and full-length p73 variants as decisive factors in cancer progression.

Authors:  D Engelmann; C Meier; V Alla; B M Pützer
Journal:  Oncogene       Date:  2014-11-10       Impact factor: 9.867

Review 3.  Reviving the guardian of the genome: Small molecule activators of p53.

Authors:  Daniel Nguyen; Wenjuan Liao; Shelya X Zeng; Hua Lu
Journal:  Pharmacol Ther       Date:  2017-03-27       Impact factor: 12.310

4.  p73 in Cancer.

Authors:  Alessandro Rufini; Massimiliano Agostini; Francesca Grespi; Richard Tomasini; Berna S Sayan; Maria Victoria Niklison-Chirou; Franco Conforti; Tania Velletri; Antonio Mastino; Tak W Mak; Gerry Melino; Richard A Knight
Journal:  Genes Cancer       Date:  2011-04

5.  APR-246 induces apoptosis and enhances chemo-sensitivity via activation of ROS and TAp73-Noxa signal in oesophageal squamous cell cancer with TP53 missense mutation.

Authors:  Teruyuki Kobayashi; Tomoki Makino; Kotaro Yamashita; Takuro Saito; Koji Tanaka; Tsuyoshi Takahashi; Yukinori Kurokawa; Makoto Yamasaki; Kiyokazu Nakajima; Eiichi Morii; Hidetoshi Eguchi; Yuichiro Doki
Journal:  Br J Cancer       Date:  2021-10-01       Impact factor: 9.075

6.  p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells.

Authors:  Luciana P Rangel; Giulia D S Ferretti; Caroline L Costa; Sarah M M V Andrade; Renato S Carvalho; Danielly C F Costa; Jerson L Silva
Journal:  J Biol Chem       Date:  2019-01-02       Impact factor: 5.157

Review 7.  Drugging the p53 pathway: understanding the route to clinical efficacy.

Authors:  Kian Hoe Khoo; Khoo Kian Hoe; Chandra S Verma; David P Lane
Journal:  Nat Rev Drug Discov       Date:  2014-03       Impact factor: 84.694

8.  APR-246/PRIMA-1(MET) rescues epidermal differentiation in skin keratinocytes derived from EEC syndrome patients with p63 mutations.

Authors:  Jinfeng Shen; Ellen H van den Bogaard; Evelyn N Kouwenhoven; Vladimir J N Bykov; Tuula Rinne; Qiang Zhang; Geuranne S Tjabringa; Christian Gilissen; Simon J van Heeringen; Joost Schalkwijk; Hans van Bokhoven; Klas G Wiman; Huiqing Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-25       Impact factor: 11.205

9.  Impaired epithelial differentiation of induced pluripotent stem cells from ectodermal dysplasia-related patients is rescued by the small compound APR-246/PRIMA-1MET.

Authors:  Ruby Shalom-Feuerstein; Laura Serror; Edith Aberdam; Franz-Josef Müller; Hans van Bokhoven; Klas G Wiman; Huiqing Zhou; Daniel Aberdam; Isabelle Petit
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-25       Impact factor: 11.205

10.  APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase.

Authors:  X Peng; M-Q-Z Zhang; F Conserva; G Hosny; G Selivanova; V J N Bykov; E S J Arnér; K G Wiman
Journal:  Cell Death Dis       Date:  2013-10-24       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.